Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of laroprovstat (AZD0780) versus placebo in adults with heterozygous familial hypercholesterolaemia
NL-OMON60506Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypercholesterolemia (FH) comparing Laroprovstat plus background lipid-lowering therapy with Placebo plus background lipid-lowering therapy (2 arms). Primary endpoint: Relative change in LDL-C from baseline to 12 weeks. Started Oct 2025; status: active, not recruiting.
02
Drugs
laroprovstat
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON60506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60506.